Recent international guidelines on dyslipidemia, such as those issued by the Ameri-can Heart Association (AHA), American College of Cardiology (ACC), Multisociety (MS), European Society of Cardiology (ESC), European Atherosclerosis Society (EAS), and Canadian Cardiovascular Society (CCS), emphasize the role of ApoB as a valuable biomarker for cardiovascular risk assessment [3,4,5]. Here, APOB is linked to metabolic syndrome.